To investigate the combined antimitotic/pro-apoptotic efficacy in established MYCN-driven neuroblastoma as a therapeutic option, we treated SHEP21N with the combination of antimitotic compounds and pro-apoptotic compounds at various dosages in a MYCN-negative and MYCN-induced setting (Figure 6A). The gene discussed is MYCN; the disease is neuroblastoma.